NPI-001

DRUG3 trials

Sponsors

Nacuity Pharmaceuticals, Inc., Arctic Therapeutics

Conditions

Alzheimer´s DiseaseRetinitis Pigmentosa (RP)Usher SyndromeUsher Syndromes

Phase 1

Safety and Efficacy of NPI-001 Tablets for RP Associated With Usher Syndrome

CompletedNCT04355689

Nacuity Pharmaceuticals, Inc.Usher Syndromes

Start: 2020-09-03End: 2026-04-22Updated: 2026-07-01

Phase 2

Safety, Tolerability and Biomarker-based Efficacy of NPI-001 (AT-001) in Subjects With MCI or Alzheimer's Disease (AD)

Active, not recruitingNCT07741526

Arctic TherapeuticsAlzheimer´s Disease

Start: 2025-10-14End: 2027-05-31Updated: 2026-08-03

Phase 3

A 24-Month Trial of NPI-001 for the Preservation of Photoreceptors in Retinitis Pigmentosa Associated With Usher Syndrome

Not yet recruitingNCT07710196

Nacuity Pharmaceuticals, Inc.Retinitis Pigmentosa (RP), Usher Syndrome

Start: 2026-08-01End: 2029-02-01Target: 80Updated: 2026-07-17